The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication
- 1 June 2004
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 19 (12), 1315-1321
- https://doi.org/10.1111/j.1365-2036.2004.01959.x
Abstract
Aims : To evaluate the role of antibiotic susceptibility for the treatment outcome of proton pump inhibitor‐dependent and independent Helicobacter pylori eradication regimens. Methods : In a placebo‐controlled clinical study of peptic ulcer patients with H. pylori infection, patients were randomized to receive lansoprazole, clarithromycin and tinidazole twice‐daily, clarithromycin and tinidazole once‐daily with lansoprazole or with placebo. Helicobacter pylori status was assessed by culture and antibiotic susceptibility by E‐test minimal inhibitory concentration (MIC) in 205 clinical isolates. Results : Primary resistance to clarithromycin and metronidazole was 1 and 76%, respectively. In metronidazole susceptible strains eradication rates were similar at > 90% for all treatment groups (P = 0.49). With low‐level metronidazole resistance (4 μg/mL < MIC < 256 μg/mL), eradication rates were similar at >75% (P = 0.80). The major difference was found at high‐level metronidazole resistance (MIC ≥ 256 μg/mL) with 95%, 58% and 21% eradication in the lansoprazole, clarithromycin and tinidazole twice‐daily, lansoprazole, clarithromycin and tinidazole once‐daily and placebo, clarithromycin and tinidazole once‐daily groups, respectively (P < 0.001). Conclusion : In the absence of antibiotic resistance, a once‐daily therapy of only clarithromycin and tinidazole can achieve a high rate of H. pylori eradication. Such a combination could offer a simpler and cheaper treatment option for developing countries. The standard, twice‐daily proton pump inhibitor‐based triple therapy was shown to be efficient in H. pylori eradication even in the presence of high‐level metronidazole resistance.Keywords
This publication has 30 references indexed in Scilit:
- Helicobacter pylori Primary Resistance to Metronidazole and Clarithromycin in BrazilAntimicrobial Agents and Chemotherapy, 2002
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2001
- Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South‐East AsiaAlimentary Pharmacology & Therapeutics, 2000
- A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication ratesAlimentary Pharmacology & Therapeutics, 1999
- Rapid Recurrence ofHelicobacter pyloriInfection in Peruvian Patients after Successful EradicationClinical Infectious Diseases, 1997
- Helicobacter pyloriReinfection Is Virtually Absent after Successful EradicationThe Journal of Infectious Diseases, 1997
- One‐week low‐dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcersAlimentary Pharmacology & Therapeutics, 1997
- Helicobacter pyloriReinfection after Apparent Eradication—The Ipswich ExperienceScandinavian Journal of Gastroenterology, 1996
- Rapid eradication of Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1995
- Short-term low-dose triple therapy for the eradication of Helicobacter pyloriEuropean Journal of Gastroenterology & Hepatology, 1994